Health In Tech, Inc. (HIT) is a leading innovator in the digital health sector, dedicated to enhancing healthcare delivery through advanced technology solutions. The company leverages state-of-the-art data analytics and proprietary software to empower healthcare providers and patients alike, facilitating informed decision-making and improved operational efficiencies. With a strong commitment to compliance and cybersecurity, HIT is adept at addressing the challenges of the rapidly evolving digital health environment. As the industry continues to grow, HIT is strategically positioned to capitalize on emerging opportunities, playing a pivotal role in the global advancement of technology-driven healthcare solutions.
| Revenue (TTM) | $34.08M |
| Gross Profit (TTM) | $20.09M |
| EBITDA | $2.43M |
| Operating Margin | -24.60% |
| Return on Equity | -4.52% |
| Return on Assets | -2.76% |
| Revenue/Share (TTM) | $0.60 |
| Book Value | $0.33 |
| Price-to-Book | 3.25 |
| Price-to-Sales (TTM) | 2.06 |
| EV/Revenue | 1.759 |
| EV/EBITDA | 294.68 |
| Quarterly Earnings Growth (YoY) | 10.30% |
| Quarterly Revenue Growth (YoY) | 9.40% |
| Shares Outstanding | $53.86M |
| Float | $20.22M |
| % Insiders | 61.95% |
| % Institutions | 4.83% |
Volatility is currently contracting
STUART, Fla., June 29, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company") was added as a member of the Russell Microcap® Index, effective when the U.S. market opens on June 29, 2026, as part of the 2026 Russell U.S. indexes reconstitution.
Health In Tech, Inc. (HIT) Q1 2026 Earnings Call Transcript
Reiterates Guidance for 2026 Annual Revenue Ranging between $45 Million and $50 Million STUART, Fla., May 13, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or "Company"), an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three months ended March 31, 2026.
STUART, Fla., April 30, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT), an AI-enabled InsurTech platform company, today announced that it will release financial results for the first quarter ended March 31, 2026, following the close of market on Wednesday, May 13, 2026.
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy PONTE VEDRA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today announced a major regulatory milestone after successfully completing its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005, the Company's investigational first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT).
STUART, Fla., April 21, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) (the "Company"), an AI-enabled InsurTech platform company, today announced that it will be participating in the Market Movers Investor Summit on Tuesday, May 5, 2026.
Health In Tech, Inc. (HIT) Q4 2025 Earnings Call Transcript
STUART, Fla., March 25, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company"), an AI-enabled InsurTech platform company, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the "PIPE") that is expected to result in gross proceeds of approximately $7.0 million before deducting placement agent fees and offering expenses.
Full year 2025 Revenues of $33.3 million, up 71% YoY Full year 2025 Adjusted EBITDA of $4.1 million, up 81% YoY STUART, Fla., March 25, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or "Company"), an AI-enabled InsurTech platform company, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HIT and any ticker you trade — then tracks every position and per-strategy win rate.
